Wed06262019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Data Recovery Review
    Data Recovery Review
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NVIDIA, DXC Technology, Immunomedics, and Natural Health and Encourages Investors to Contact the Firm


NEW YORK, Feb. 10, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NVIDIA Corporation, DXC Technology Company, Immunomedics, Inc., and Natural Health Trends Corp.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.  Additional information about each case can be found at the link provided.
NVIDIA Corporation (NASDAQ: NVDA)Class Period: August 10, 2017 - November 15, 2018Lead Plaintiff Deadline: February 19, 2019The complaint alleges that throughout the class period defendants assured investors that the company followed the market closely and could adjust to rapid changes in the cryptocurrency markets.  Even as analysts increasingly began to question the company’s ability to manage inventory in the face of an uncertain cryptocurrency market, defendants touted that NVIDIA and its executives are “masters at managing our channel, and we understand the channel very well.”  NVIDIA also repeatedly assured investors that surging demand for Graphics Processing Units (“GPUs”) among cryptocurrency miners would not have a negative impact on the company because of strong demand for GPUs by NVIDIA’s core customer base of computer gamers. To learn more about the NVIDIA class action go to: http://bespc.com/nvda/.DXC Technology Company (NYSE: DXC)Class Period: February 8, 2018 - November 6, 2018Lead Plaintiff Deadline: February 25, 2019The complaint alleges that throughout the class period defendants made false and misleading statements and/or failed to disclose adverse information regarding the company’s business and prospects.  Specifically, the complaint alleges that defendants failed to disclose that the company had changed or planned to change the operations of its sales teams, deploying generalized sales teams as opposed to the specialized teams that were better capable of delivering specialized services to its clients; that the company’s workforce optimization strategy of sharply reducing staff while reducing costs was resulting in a shortage of sales personnel who could execute on deman...


Posted: 2019-02-10 22:00:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NVIDIA, DXC Technology, Immunomedics, and Natural Health and Encourages Investors to Contact the Firm | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Traders Prepare For Earnings Season, Slow Growth Expectations

Thu, 18 Apr 2019 11:31:00 GMT

ETFs are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk, consequences of seeking daily leveraged investment results and intend to ...

On Investments: The near insanity of investing at 100 times revenue

Tue, 19 Feb 2019 22:17:00 GMT

You see this behavior mostly with young biotechnology stocks and fledgling technology stocks ... Part of investors’ excitement about Tellurian is based on plans for India to import a lot of natural ...

Three Sky-High Stocks To Avoid

Tue, 19 Feb 2019 10:04:00 GMT

You see this behavior mostly with young biotechnology stocks and fledgling technology stocks ... Part of investors’ excitement about Tellurian is based on plans for India to import a lot of natural ...

John Dorfman: The near insanity of investing at 100 times revenue

Sun, 17 Feb 2019 17:30:00 GMT

You see this behavior mostly with young biotechnology stocks and fledgling technology stocks ... Part of investors’ excitement about Tellurian is based on plans for India to import a lot of natural ...

Amgen Gets FDA Approval For PCSK9 Inhibitor

Mon, 11 Jul 2016 03:27:00 GMT

Amgen pointed out that Repatha is a human monoclonal antibody, which blocks a protein known as proprotein convertase subtilisin/kexin type 9 (PCSK9) that inhibits the body's natural system ... based ...

Related Bing Web Search

  • No items found
  • Related News Story Videos From Youtube

    All NASDAQ Companies · Ticker Symbols & Key Market Information


    Related Videos On: All NASDAQ Companies · Ticker Symbols & Key Market Information






    Blow Us A Whistle

    Comments (Whistles) Designed By Disqus




    Company Information

    Official Content Providers











    PRIVACY POLICY

    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.